乙型肝炎失代偿期肝硬化及慢性肝衰竭患者的呼出气代谢组学差异性分析＊

目的 研究乙型肝炎失代偿期肝硬化与慢性肝衰竭患者的呼出气代谢组学差异，以探索潜在的能预测严重肝病进展的无创生物标志物。方法 采用全二维气相色谱-飞行时间质谱（comprehensive two-dimensional gas chromatography tandem time-of-flight mass spectrometry, GC × GC-TOF-MS）研究乙型肝炎失代偿期肝硬化及慢性肝衰竭两组患者的呼出气代谢产物，以主成分分析（principal component analysis, PCA）和正交偏最小二乘判别法（orthogonal partial least square discriminant analysis, OPLS-DA）比较挥发性有机化合物（volatile organic compound,VOC）的性质及含量，曲线下面积（area under the curve,AUC）和受试者工作特性（receiver operating characteristic,ROC）曲线建立预测模型。结果 与失代偿期肝硬化组相比，慢性肝衰竭组的1-dodecanol、1-1-cyclohexen-1-yl-ethanone、1-1-methylethoxy-2-propanone、o-cymene及carbon dioxide含量明显降低。ROC曲线分析显示，十二烷醇（1-dodecanol）可鉴别失代偿期肝硬化与慢性肝衰竭（ROC曲线下面积 = 0.825），且敏感性77.8%，特异性99.23%。结论 十二烷醇可作为一种潜在的生物标志物，预测乙肝失代偿期肝硬化进展为慢性肝衰竭的风险，同时为无创检测方法评估、预测慢性肝病的预后提供物质基础。

Analysis of Exhaled Gas Metabolites in Patients with Decompensated Cirrhosis and Chronic Liver Failure of Hepatitis B

Objective To study the difference of exhaled gas metabonomics between patients with decompensated hepatitis B cirrhosis and chronic hepatic failure in order to explore potential non-invasive biomarkers for predicting the progression of severe liver diseases.Methods With the advent of comprehensive two-dimensional gas chromatography tandem time-of-flight mass spectrometry (GC×GC-TOF-MS), we studied the difference of exhaled gas metabonomics between patients with decompensated cirrhosis and chronic hepatic failure of hepatitis B. Principal component analysis (PCA) and Orthogonal Partial Least Square Discriminant Analysis (OPLS-DA) were performed to compare the contents of the volatile organic compounds (VOCs). Area under the curve (AUC) and receiver operating characteristic (ROC) curves were used to build a predictive model.Results Compared with decompensated cirrhosis group, the contents of 1-dodecanol, 1-1-cyclohexen-1-yl-ethanone, 1-1-methylethoxy-2-propanone, o-cymene and carbon dioxide in chronic hepatic failure group were significantly lower. ROC curve analysis showed that 1-dodecanol could identify decompensated cirrhosis and chronic hepatic failure patients (area under ROC curve = 0.825), with sensitivity of 77.8% and specificity of 99.23%.Conclusion 1-dodecanol can be used as a potential non-invasive biomarker to predict the risk of hepatitis B decompensated cirrhosis progressing to chronic liver failure, and to provide a foundation for noninvasive detection methods to evaluate and predict the prognosis of chronic liver diseases.